Supported by an independent educational grant from Jazz Pharmaceuticals, Inc.

Posters

Patient Perspective on Barriers to Diagnosis and Treatment of Tardive Dyskinesia: Results From a Cross-Sectional Survey

Tardive dyskinesia (TD) is a hyperkinetic movement disorder resulting from chronic exposure to antipsychotics.

All Posters

Real-World Antipsychotic and Vesicular Monoamine Transporter Type 2 Inhibitor Treatment Patterns in Patients Newly Diagnosed With Tardive Dyskinesia

Tardive dyskinesia (TD) is associated with antipsychotic (AP) use Deutetrabenazine (DTBZ) is a vesicular monoamine transporter type 2 inhibitor (VMAT2i) approved to treat TD. 

Exposure–Response Analysis to Compare Changes in the Clinical Endpoints for Tardive Dyskinesia and Chorea in Huntington Disease Following Once-Daily and Twice-Daily Tablet Formulations of Deutetrabenazine

Exposure-Response models using predicted exposure of deutetrabenazine’s active metabolites following BID and QD formulation administration, and therapeutic responses in the phase 3 TD and HD studie

Drug–Drug Interactions With Vesicular Monoamine Transporter 2 Inhibitors: Population Estimate of Patients With Tardive Dyskinesia at Risk in Real-World Clinical Practice

This study estimated proportions of patients with TD at risk of DDIs with valbenazine/deutetrabenazine in real-world practice.